{"disease":{"id":"locoregional-recurrence","name":"locoregional recurrence"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07190443","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Japanese Foundation for Cancer Research","has_results":false},{"nct_id":"NCT05988112","title":"Locoregional Recurrence of Breast Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":265,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05467891","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Oana Danciu","has_results":false},{"nct_id":"NCT04550910","title":"RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":166,"lead_sponsor_name":"National Cancer Institute, Egypt","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}